EUVIMEDEUVIMED entdecken
Crossref

Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Chien-Chung Wang, Chih-Chun Wang, Chuan-Chien Yang, Tzer-Zen Hwang, Ching-Feng Lien, Yu-Chen Shih, Shyh-An Yeh, Meng-Che Hsieh iD

Head & Neck · 2025

DOI: 10.1002/hed.70104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Chien-Chung Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known regarding the interaction between vaccination and immunotherapy in cancer patients. Herein, we conducted a retrospective study to evaluate the impact of coronavirus disease 2019 (COVID‐19) vaccinated status on survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICI).

Methods

Patients who were treated with ICI for their R/M HNSCC were reviewed retrospectively. Patients who received at least one shot of the vaccine against COVID‐19 were recruited into our study. Patients were stratified into fully vaccinated (FV) and partially vaccinated (PV) according to their vaccination status. Kaplan–Meier curves were estimated for progression‐free survival (PFS) and overall survival (OS).

Results

A total of 127 patients were enrolled in our study for oncologic outcomes evaluation, including 70 FV and 57 PV. For the total population, the median PFS was 4.6 months and OS was 23.7 months. After stratifying according to COVID‐19 vaccination status, the median PFS was 6.2 months in FV and 3.1 months in PV ( p = 0.010). The median OS was 32.5 months in FV and 10.3 months in PV ( p < 0.001). After the last dose of vaccination, the median neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio were significantly lower in FV than in PV ( p < 0.001). No new safety issues were found in our patient cohort and were insignificant between the FV and PV groups.

Conclusions

R/M HNSCC patients with FV had significantly lower NLR and PLR, and had better survival when treated with ICI without increasing treatment toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalCOVID-19Head and Neck NeoplasmsCOVID-19 VaccinesHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overSARS-CoV-2Treatment Outcome

Stichwörter der Autor:innen

COVID‐19immune checkpoint inhibitorsrecurrent or metastatic head and neck squamous cell carcinomasurvivalvaccinated status

Substanzen

Immune Checkpoint InhibitorsCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan.
  • College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Department of Otolaryngology, E-Da Cancer Hospital, Kaohsiung, Taiwan.
  • Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan.
  • Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan.

ORCID-Profile: Meng-Che Hsieh

Zitieren

APA

Wang, C. C., Wang, C. C., Yang, C. C., Hwang, T. Z., Lien, C. F., Shih, Y. C., Yeh, S. A., & Hsieh, M. C. (2025). Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70104

Vancouver

Wang CC, Wang CC, Yang CC, Hwang TZ, Lien CF, Shih YC, et al. Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. 2025. doi:10.1002/hed.70104

BibTeX
@article{Wang2025,
  author = {Wang, Chien-Chung and Wang, Chih-Chun and Yang, Chuan-Chien and Hwang, Tzer-Zen and Lien, Ching-Feng and Shih, Yu-Chen and Yeh, Shyh-An and Hsieh, Meng-Che},
  title = {Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.70104}
}
Kostenlos starten →